In regards to the stock of this high-quality pharmaceutical distributor, the author of today’s article declares that it “is not just cheap – it’s incredibly cheap.” But what about concerns the market currently has about this stock – namely Amazon’s entrance into the drug distribution space and White House rhetoric on drug prices? The author lays out how, under even the worst-case scenario for this company, it’s a “heads we win, tails we get less, but we still win” scenario for investors. For more, CLICK HERE.